Mark Harrington of the Treatment Action Group predicts the coming challenges in AIDS activism and explains what can be done about them.

Seth Berkley, MD, explains what we’ve learned about challenge to build better vaccine after recent vaccine failures and lays out next steps

Abbott Laboratories has developed a tablet version of its protease inhibitor (PI) Norvir (ritonavir), typically used in drug regimens to boost...

David Evans talks with Ian McGowan from University of Pittsburgh in Pennsylvania, about the promise of pre-exposure prophylaxis

Harvard’s Sofia Gruskin talks about the impact of human rights struggles on the AIDS epidemic and the legacy of Dr. Jonathan Mann.

A medicinal compound in milk thistle, a flowering member of the daisy family, may benefit liver function in people infected with HIV and the h...

HIV-positive patients with high blood pressure and on medications known to increase the risk of kidney damage are at the highest risk for kidn...

The CDC’s Kevin Fenton, MD, PhD, tells Regan Hofmann about the new HIV incidence report and the possibility of a national HIV strategic plan

The CDC’s Kevin Fenton, MD, PhD, tells Regan Hofmann about the new HIV incidence report and the possibility of a national HIV strategic plan

Treatment with a tesamorelin resulted in a significant loss of visceral adipose tissue (VAT)—deep belly fat—compared with a placebo